Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns

Jefferies has recommended quality, low-stress stocks amid increasing market volatility related to artificial intelligence investments. They specifically highlight AbbVie (ABBV), predicting nearly 28% compound annual earnings growth for 2026-2027 and a free cash flow yield of 5.2%. AbbVie's first-quarter net revenues reached $15 billion, led by its immunology portfolio of $7.3 billion. The stock has appreciated 25% over the last three months and 37% in the past year, offering a yield of 2.7%. This is important for investors as it suggests stable investment options amidst market fluctuations.